Pruritic Papular Eruption Associated with HIV: Definition and Dermatological Characteristics
The pruritic papular eruption linked to HIV (Human Immunodeficiency Virus) is frequently established as the most prevalent cutaneous manifestation during the course of the infection. Categorized within the spectrum of lesions, prurigo, this condition affects between 18% and 46% of people carrying HIV at some point. This condition can cause considerable distress to the patient, given its capacity to generate disfigurement and stigmatization, added to the fact that the response to treatment is often unsatisfactory in many cases.
Causes and Differential Diagnosis of Pruritic Dermatosis due to HIV
From a technical perspective, this rash is considered a diagnosis of exclusion. This means it is only applied after rigorously ruling out all other known cutaneous etiologies. Currently, a single, definitive cause for this dermatosis has not been identified. Various factors have been investigated, such as adverse drug reactions, autoimmune phenomena, autoimmunity, arthropod bites, arthropods, or even direct infiltration of the virus into the skin tissues; however, none have been conclusively proven.
Unfortunately, medical literature tends to group a heterogeneity of different dermatological conditions under the designation «pruritic papular eruption associated with HIV.» It is essential to investigate and rule out the following entities before issuing a definitive diagnosis of HIV-associated prurigo:
- Bacterial Folliculitis
- Infections staphylococcal
- Malassezia Dermatitis
- Folliculitis eosinophilic
- Infections caused by the Herpes virus simplex
- Opportunistic Pseudomonas infections
- Gram-negative bacillus infection (e.g., *Klebsiella*, *Enterobacter*)
- Demodicidosis (scabies caused by *Demodex* mites)
- Cutaneous reactions to insect bites
- Granulomas specific
- Skin lesions drug-induced
- Neurological Lichenoid y dermatitis granulomatous manifestations related to AIDS
- Granulomatous reactions of post-viral origin
- Severe acne vulgaris
Generally, the formal establishment of this diagnostic exclusion and the confirmation of HIV-associated prurigo often require histopathological analysis via a skin biopsy. biopsy cancer.
Clinical Manifestations and Typical Distribution of the Papular Eruption
The most dominant symptom in the pruritic papular eruption associated with HIV is the intensity of the itching. Morphologically, it presents as a collection of erythematous papules, well-demarcated, and showing signs of active scratching. These lesions exhibit a diffuse and symmetrical symmetrical distribution across the body surface. The preferred areas for their location are the trunk and extremities. It is important to note that mucosal areas (mouth, eyes, genitals), as well as the palms of the hands and interdigital spaces, usually remain unaffected in most cases.
The correct identification of the pruritic papular eruption associated with HIV requires an exhaustive differential diagnosis, as many other pathologies common in immunosuppressed patients can replicate its initial clinical presentation.
This cutaneous manifestation represents the symptomatic presentation of HIV in a considerable percentage of cases (between 25% and 79%). Furthermore, it functions as a sign sign of advanced disease, appearing three times more often when the lymphocytes CD4 count falls below 200 x109/L.
Recommended Treatment Options for HIV-Associated Prurigo
Unfortunately, the pruritic papular eruption linked to HIV frequently exhibits notable resistance to established conventional treatments. Despite this, the medical community has several therapeutic approaches that have proven effective for a subset of patients suffering from this condition.
As an initial strategy, the primary recommendation includes the application of corticosteroids topical corticosteroids, supplemented by the rigorous use of emollients emollients and oral antihistamines, prioritizing the latter due to their safety profile and ease of access.
In situations where the initial response is inadequate, the introduction of phototherapy, specifically using UVB or PUVA modalities, should be seriously considered. Although this option is usually effective, the average interval until the recurrence of the skin alteration is around 8 weeks.
Another therapeutic agent with demonstrated utility is oxpentifylline. It is theorized that its mechanism of action resides in its capacity for inhibiting tumor necrosis factor alpha (TNFTNFα). The most reported dosage consists of 400 mg administered three times a day, maintaining this regimen for a minimum of 8 weeks to evaluate the response.
There is a diversity of opinions regarding whether HAART (Highly Active Antiretroviral Therapy) exerts a constant influence on the rash, as the response varies significantly among patients. Nevertheless, since some individuals achieve notable and lasting remissions, it has been suggested that papular prurigo could be used as an acceptable clinical indicator for initiating HAART in certain specific circumstances.
